SCHEMBL149206

SCHEMBL149206

[CH2]/C(=C/C)CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL149207 1.00
SCHEMBL8593407 0.80
SCHEMBL8707961 0.80
SCHEMBL8593409 0.80
SCHEMBL8700267 0.78
SCHEMBL8700268 0.78
SCHEMBL9381006 0.78
SCHEMBL9381005 0.78
SCHEMBL2889952 0.76 CES2 (0.48)
SCHEMBL2889953 0.76 CES2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP claimed
US-20240229089-A1 A process for enzymatic synthesis of amides from amines and carboxylic acids or esters XP CHEMISTRIES AB (SE) 2024-07-11 US disclosed
US-20240208909-A1 SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2024-06-27 US disclosed
EP-3835298-B1 NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC (US) 2024-06-26 EP disclosed
US-12011445-B2 Prevention of pancreatic cell degeneration MELIOR PHARMACEUTICALS I, INC. (US) 2024-06-18 US disclosed
WO-2024119028-A1 SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF ACCUTAR BIOTECHNOLOGY, INC. (US) 2024-06-06 WO disclosed
US-11999741-B2 Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one CARDURION PHARMACEUTICALS, INC. (US) 2024-06-04 US disclosed
US-11992470-B2 Stable aqueous capsaicin injectable formulations and medical uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2024-05-28 US disclosed
EP-4366833-A1 CANCER THERAPEUTICS Universitat de Barcelona (ES) 2024-05-15 EP disclosed
US-20240140983-A1 SINGLE STRANDED DNA ENZYME INHIBITORS MASSEY UNIVERSITY (NZ) 2024-05-02 US disclosed
US-20020077316-A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses ESPERION THERAPEUTICS, INC. 2002-06-20 US disclosed
WO-2002043765-A2 PHARMACEUTICAL FORMULATIONS COMPRISING PACLITAXEL, DERIVATIVES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TRANSFORM PHARMACEUTICALS, INC. (US) 2002-06-06 WO disclosed
EP-1204626-A1 ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF Esperion Therapeutics Inc. (US) 2002-05-15 EP disclosed
WO-2002030884-A2 SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2002030860-A2 KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2002030863-A2 ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
US-20020045639-A1 COMBINATION OF HUPERZINE AND NICOTINIC COMPOUNDS AS A NEUROPROTECTIVE AGENT US ARMY, SECRETARY OF THE ARMY 2002-04-18 US disclosed
WO-2002030882-A2 SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2002-04-18 WO disclosed
WO-2002011712-A2 COMBINATION OF HUPERZINE AND NICOTINIC COMPOUNDS AS A NEUROPROTECTIVE AGENT GEORGETOWN UNIVERSITY (US) 2002-02-14 WO disclosed
WO-2000059855-A1 ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF ESPERION THERAPEUTICS, INC. (US) 2000-10-12 WO disclosed